的申請版本 香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確 性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 Wuhan Ammunition Life-tech Co., Ltd.* 武漢艾米森生命科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）╱證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即 代表 閣下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或包銷團成員表示 同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據經香港公司註冊處處長登記 的本公司招股章程作出投資決定；有關文本將於發售期內向公眾人士派發。 警 告 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據 本文件中的資料作出任何投資決定； (b) 在聯交所網 ...

Core Viewpoint - Early cancer detection is crucial for reducing mortality rates among cancer patients, and the study highlights the potential of phosphatidylserine-positive extracellular vesicles (PS+ EV) as a specific biomarker for multiple operable cancers [2][10]. Group 1: Importance of Early Cancer Detection - Most cancers are diagnosed at advanced stages, limiting treatment options and chances of cure [4]. - Current cancer diagnostics rely heavily on imaging techniques and histopathological analysis, which have inherent risks and insufficient sensitivity for early-stage cancers [4][5]. - There is a critical need for sensitive and accessible screening methods to detect various cancer types at earlier, more treatable stages [4]. Group 2: Liquid Biopsy and Extracellular Vesicles - Liquid biopsy is a minimally invasive and sensitive detection method that can identify cancer at earlier stages [5]. - Blood is the primary biological fluid for analyzing circulating tumor-derived components, including circulating tumor cells (CTC), extracellular vesicles (EV), and various acellular molecules [5][6]. - Tumor-derived EVs are released by metabolically active and proliferating cancer cells, providing a promising avenue for early diagnosis and clinical decision-making [6][7]. Group 3: Research Findings - The study identified phosphatidylserine (PS) as a tumor-specific EV biomarker, leading to the development of a blood biopsy method called "PSEV-MultiCancer" [7][11]. - In a clinical sample of 1869, including 1269 cancer patients, PSEV-MultiCancer achieved an area under the curve (AUC) of 0.932, with a positive detection rate of 84.7% [7]. - For early-stage (I-II) cancers, the sensitivity reached 74.7% and specificity was 89.8% [7]. Group 4: Validation and Implications - The method underwent blind validation in three independent clinical cohorts, yielding AUC values of 0.97, 0.99, and 0.89, with an average sensitivity of 84.1% and average specificity of 97.3% [8]. - These findings support PSEV-MultiCancer as a promising non-invasive early cancer detection tool, aiding timely therapeutic interventions for patients [10][11].